SEARCH:   Advanced

Blood, 15 February 2007, Vol. 109, No. 4, pp. 1720-1727. Prepublished online as a Blood First Edition Paper on October 26, 2006; DOI 10.1182/blood-2006-04-018143. This Article Full Text (PDF) Supplemental Table All Versions of this Article: blood-2006-04-018143v1 109/4/1720    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dijkman, R. Articles by Tensen, C. P Search for Related Content PubMed PubMed Citation Articles by Dijkman, R. Articles by Tensen, C. P Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 19, 2006 Accepted August 29, 2006 Gene expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities Remco Dijkman, Remco van Doorn, Karoly Szuhai, Rein Willemze, Maarten H Vermeer, and Cornelis P Tensen* Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, Netherlands * Corresponding author; email: c.p.tensen{at}lumc.nl. CD4+CD56+ hematodermic neoplasm (CD4+CD56+HN) is an aggressive hematopoietic malignancy with distinct clinicopathologic and immunophenotypical features that commonly involves the skin, bone marrow and blood. Differentiation from cutaneous myelomonocytic leukemia (c-AML) may be exceedingly difficult and requires extensive phenotyping. The molecular mechanisms involved in the development of CD4+CD56+HN are largely unresolved. Moreover, recurrent chromosomal alterations have not yet been precisely defined in CD4+CD56+HN and c-AML. In the present study an integrated genomic analysis using expression profiling and array-based CGH was performed on lesional skin biopsy samples of patients with CD4+CD56+HN and c-AML. Our results demonstrate that CD4+CD56+HN and c-AML show distinct gene expression profiles and distinct patterns of chromosomal aberrations. CD4+CD56+HN is characterized by recurrent deletion of regions on chromosome 4 (4q34), chromosome 9 (9p13-p11 and 9q12-q34) and chromosome 13 (13q12-q31), that contain several tumor suppressor genes with diminished expression (Rb1, LATS2). Elevated expression of the oncogenes HES6, RUNX2 and FLT3 was found, but was not associated with genomic amplification. We noted high expression of various plasmacytoid dendritic cell (pDC)-related genes, pointing to the cell of origin of this malignancy. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Marafioti, J. C. Paterson, E. Ballabio, K. K. Reichard, S. Tedoldi, K. Hollowood, M. Dictor, M.-L. Hansmann, S. A. Pileri, M. J. Dyer, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells Blood, April 1, 2008; 111(7): 3778 - 3792. [Abstract] [Full Text] [PDF] B. Fancke, M. Suter, H. Hochrein, and M. O'Keeffe M-CSF: a novel plasmacytoid and conventional dendritic cell poietin Blood, January 1, 2008; 111(1): 150 - 159. [Abstract] [Full Text] [PDF] S. C.-S. Hu, K.-B. Tsai, G.-S. Chen, and P.-H. Chen Infantile CD4+/CD56+ hematodermic neoplasm Haematologica, September 1, 2007; 92(9): e91 - e93. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020